US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,551.80

+8.540.55%

Number of Gainers:9

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,575.99

Open:1,545.17

Low:1,541.96

Close:1,543.26

Loading ...

Chimerix Cut to Hold From Buy by Jones Trading

Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

SIGA Technologies (NASDAQ:SIGA) shareholders have endured a 3.0% loss from investing in the stock three years ago

Simply Wall St.

Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients

US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms

Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential

Jazz Pharma Seen Poised to Do More Deals -- Market Talk

Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval

Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel

CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz

Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?

Simply Wall St.

Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says

MT Newswires Live

Chimerix Shares Take Flight on Takeover by Jazz Pharmaceuticals

Chimerix, Inc. : H.c. Wainwright Cuts Target Price to $8.55 From $11

THOMSON REUTERS

Chimerix Shares Jump 69.4% to More Than Three Year High After Jazz Pharmaceuticals to Buy Co for $935 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1551.8009,"timestamp":1741208399999,"preClose":1543.2614,"halted":0,"volume":166837424,"delay":0,"changeRate":0.005533,"change":8.539551,"pbRate":3.824438,"amount":3385093748.92931,"amplitude":0.02205,"prevYearClose":1284.7982,"fiveDayClose":1514.4326,"twentyDayClose":1341.489,"turnoverRate":0.059436,"marketCap":175802911591.5,"floatMarketCap":175019023106.5,"peRate":756.174276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1575.9855,"amplitude":0.02205,"preClose":1543.2614,"low":1541.9567,"pbRate":"3.824438","latestPrice":1551.8009,"volume":166837424,"delay":0,"open":1545.173,"prevYearClose":1284.7982,"prevWeekClose":1535.672,"prevMonthClose":1535.672,"prevQuarterClose":1284.7982,"fiveDayClose":1514.4326,"twentyDayClose":1341.489,"sixtyDayClose":1289.8053,"secType":"PLATE","market":"US","turnoverRate":0.059436,"peRate":756.174276,"marketCap":175802911591.5,"floatMarketCap":175019023106.5,"timestamp":1741208399999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":9,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517155097","title":"Chimerix Cut to Hold From Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2517155097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517155097?lang=en_us&edition=fundamental","pubTime":"2025-03-06 19:35","pubTimestamp":1741260900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 06:35 ET (11:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMRX","BK4583"],"gpt_icon":0},{"id":"2517156195","title":"Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156195","media":"Simply Wall St.","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156195?lang=en_us&edition=fundamental","pubTime":"2025-03-06 19:23","pubTimestamp":1741260214,"startTime":"0","endTime":"0","summary":"One of the biggest stories of last week was how Emergent BioSolutions Inc.  shares plunged 20% in the week since its latest full-year results, closing yesterday at US$5.80. Revenues of US$1.0b came in 5.4% below estimates, but statutory losses were well contained with a per-share loss of US$3.60 being some 13% smaller than what the analysts were predicting. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.Check out our latest analysis for Emergent BioSolutions","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emergent-biosolutions-inc-nyse-ebs-112334013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EBS","BK4583","NYSE"],"gpt_icon":0},{"id":"2517155431","title":"SIGA Technologies (NASDAQ:SIGA) shareholders have endured a 3.0% loss from investing in the stock three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2517155431","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517155431?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:56","pubTimestamp":1741258566,"startTime":"0","endTime":"0","summary":"Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term SIGA Technologies, Inc.  shareholders, since the share price is down 22% in the last three years, falling well short of the market return of around 38%. Furthermore, it's down 18% in about a quarter. That's not much fun for holders.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Check out our latest analysis for SIGA Technologies. SIGA Technologies shareholders have received returns of 17% over twelve months , which isn't far from the general market return. That gain looks pretty satisfying, and it is even better than the five-year TSR of 7% per year. It is possible that","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/siga-technologies-nasdaq-siga-shareholders-105606482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","NVIW.SI","SIGA","PSQ","BK4007","USAW.SI","BK4583","BK4112","SQQQ","QID","USJW.SI","BK4588","QLD","IE00B64PRP62.GBP","TQQQ","IE00BGHQF748.EUR","NQmain","BK4585",".IXIC","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","MNQmain","LU2095319765.USD","IE00BKPKM429.USD","TSYW.SI"],"gpt_icon":1},{"id":"2517922071","title":"Viatris to Present at the Barclays 27th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2517922071","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517922071?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:30","pubTimestamp":1741210200,"startTime":"0","endTime":"0","summary":"PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. , a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/viatris-present-barclays-27th-annual-213000952.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-present-barclays-27th-annual-213000952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","BK4588","VTRS","BK4007","BK4583","BK4137","LU1839511570.USD","BK4585","LU2087621335.USD"],"gpt_icon":0},{"id":"2517212219","title":"US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517212219","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517212219?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:21","pubTimestamp":1741209694,"startTime":"0","endTime":"0","summary":"UPDATE 2-US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patientsAdds analyst comments in paragraphs 7-9; CEO comments in paragraphs 11 & 12 and details throughoutBy Chris","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO1TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139","BK4585","VTRS","BK4583","BK4007","LU1839511570.USD","LU2087621335.USD","BK4588"],"gpt_icon":0},{"id":"2517921969","title":"US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921969?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:14","pubTimestamp":1741209258,"startTime":"0","endTime":"0","summary":"US FDA expands use of allergic reaction nasal spray in people between 15-30 kilogramsMarch 5  - The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' SPRY.O nasal spray for severe allergic reactions in patients who weigh between 15 to 30 kilograms, the company said on Wednesday.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO1TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4007","SPRY","VTRS","BK4588","LU1839511570.USD","BK4585","BK4139","LU2087621335.USD"],"gpt_icon":0},{"id":"2517492387","title":"Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2517492387","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517492387?lang=en_us&edition=fundamental","pubTime":"2025-03-06 02:55","pubTimestamp":1741200939,"startTime":"0","endTime":"0","summary":"Chimerix (CMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Thome from TD Cowen ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-nda-submission-boost-chimerixs-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-nda-submission-boost-chimerixs-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","CMRX","BK4139"],"gpt_icon":0},{"id":"2517947325","title":"Jazz Pharma Seen Poised to Do More Deals -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517947325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517947325?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:37","pubTimestamp":1741196220,"startTime":"0","endTime":"0","summary":"1237 ET - Jazz Pharmaceuticals' move to buy Chimerix could be the start of deal-making by the biopharma, analysts at Piper Sandler say. Piper's David Amsellem and Alex von Riesemann say the $935 million deal is a sensible and targeted use of capital that doesn't get in the way of Jazz's ability to execute on additional M&A and doesn't entail Jazz taking on development risk. Piper notes that Jazz management has previously touted capacity for a multi-billion-dollar transaction or series of deals, and the analysts say they would like to see Jazz turn its attention to bolstering its epilepsy franchise. Jazz up 2% to $141.67. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4139","CMRX","IE00BN0W2W23.USD","JAZZ","LU0109394709.USD","LU0320765992.SGD","BK4532","BK4007","BK4583","LU0823416689.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","BK4533"],"gpt_icon":0},{"id":"2517476589","title":"Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2517476589","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517476589?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:25","pubTimestamp":1741195535,"startTime":"0","endTime":"0","summary":"Jefferies analyst Maury Raycroft downgraded the rating on Chimerix (CMRX – Research Report) to a Hold today, setting a price target of $8.50. Maury...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-chimerix-amid-acquisition-and-uncertainties-in-drug-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-chimerix-amid-acquisition-and-uncertainties-in-drug-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMRX","BK4139","BK4583"],"gpt_icon":0},{"id":"2517421289","title":"Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2517421289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517421289?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:21","pubTimestamp":1741195273,"startTime":"0","endTime":"0","summary":"Stifel reiterated a Buy rating and $230 price target on Jazz Pharmaceuticals (JAZZ) after the company agreed to acquire Chimerix (CMRX). The firm s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/chimerix-deal-represents-clear-strategic-fit-for-jazz-says-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/chimerix-deal-represents-clear-strategic-fit-for-jazz-says-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","IE00BN0W2W23.USD","BK4533","JAZZ","SF","BK4127","LU0823416689.USD","BK4139","LU0109394709.USD","BK4007","CMRX","IE00BN0W2T93.GBP","BK4532","LU0889565916.HKD","LU0320765992.SGD","IE00BN0W2V16.EUR"],"gpt_icon":0},{"id":"2517424849","title":"CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz","url":"https://stock-news.laohu8.com/highlight/detail?id=2517424849","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517424849?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:06","pubTimestamp":1741194389,"startTime":"0","endTime":"0","summary":"The major averages opened the season broadly lower, with the Dow and S&P 500 continuing yesterday’s declines amid ongoing uncertainty around Presid...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crowdstrike-reports-q4-beat-jazz-to-acquire-chimerix-morning-buzz?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crowdstrike-reports-q4-beat-jazz-to-acquire-chimerix-morning-buzz?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4534","OEF","OEX","SDS","SPXU","VOO","BK4504","BK4585",".SPX","IVV","SH","BK4550","BK4139","UPRO","BK4588","SSO","ESmain","SPY","CMRX","BK4559","BK4583"],"gpt_icon":0},{"id":"2517921137","title":"Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921137","media":"Simply Wall St.","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921137?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:06","pubTimestamp":1741194360,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ebs/emergent-biosolutions/news/is-emergent-biosolutions-nyseebs-weighed-on-by-its-debt-load","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EBS","NYSE","BK4139","EBIT","BK4583"],"gpt_icon":0},{"id":"2517462649","title":"Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2517462649","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517462649?lang=en_us&edition=fundamental","pubTime":"2025-03-05 23:51","pubTimestamp":1741189907,"startTime":"0","endTime":"0","summary":"Chimerix  was a prime acquisition candidate for Jazz Pharmaceuticals  due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.Shares of Chimerix were up almost 69% in recent trading.Price: 8.43, Change: +3.47, Percent Change: +69.96","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4583","IE00BN0W2W23.USD","BK4533","JAZZ","LU0823416689.USD","BK4139","LU0109394709.USD","BK4007","CMRX","IE00BN0W2T93.GBP","BK4532","LU0889565916.HKD","LU0320765992.SGD","IE00BN0W2V16.EUR"],"gpt_icon":0},{"id":"2517948005","title":"Chimerix Shares Take Flight on Takeover by Jazz Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517948005?lang=en_us&edition=fundamental","pubTime":"2025-03-05 23:00","pubTimestamp":1741186800,"startTime":"0","endTime":"0","summary":"Chimerix shares surged to a multi-year high Wednesday after the biopharmaceutical company agreed to be acquired by larger peer Jazz Pharmaceuticals for about $935 million.Jazz is paying $8.55 a share in cash for Chimerix, a 72% premium to Tuesday's closing price.Shares of the Durham, N.C., company were recently up 70% at $8.41, reaching levels not seen since 2021.Chimerix shares were trading as low as 75 cents last August before the stock began to rally late last year on hopes for its dordaviprone, which is under Food and Drug Administration review for accelerated approval in a rare, high-grade brain tumor.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IE00BN0W2V16.EUR","BK4583","CMRX","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4533","LU0109394709.USD","BK4139","JAZZ","LU0889565916.HKD","BK4532","BK4007","LU0320765992.SGD"],"gpt_icon":0},{"id":"2517484719","title":"Chimerix, Inc. : H.c. Wainwright Cuts Target Price to $8.55 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484719?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:56","pubTimestamp":1741186617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nAZN3I0IJO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","CMRX","BK4139"],"gpt_icon":0},{"id":"2517191064","title":"Chimerix Shares Jump 69.4% to More Than Three Year High After Jazz Pharmaceuticals to Buy Co for $935 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191064?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:34","pubTimestamp":1741185242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO1CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","CMRX","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":8,"pageCount":1,"totalSize":127}]}}